FDC Limited announced its financial results for the period ended March 31, 2026, at a board meeting held on May 27, 2026, alongside confirmation of an interim dividend of ₹5 per equity share declared earlier in February 2026. The announcement was submitted to the NSE under the symbol FDC (ISIN: INE258B01022).

Dividend Details

The interim dividend of ₹5 per equity share of face value ₹1 each was declared by the board on February 05, 2026, representing a payout of 500% on the face value. This is the dividend applicable to FY2026 and is the only dividend declared for the financial year based on available exchange filings.

Since market quote data is currently unavailable, a precise dividend yield calculation cannot be provided at this time. Investors should reference the current NSE market price of FDC to compute yield, using the formula: (₹5 / current market price) x 100.

Year-on-Year Comparison

The FY2026 interim dividend of ₹5 per share is identical to the interim dividend of ₹5 per share declared on November 06, 2024, for FY2025. On a like-for-like basis, the per-share payout has remained flat year-on-year, indicating no incremental reward to shareholders despite the full-year results now being available.

Long-Term Dividend Trend

FDC's dividend history reflects a substantial and consistent upward trajectory over the past decade and a half:

The jump from ₹2.25 in FY2017 to ₹5.00 in FY2025 represents a significant long-term increase in absolute dividend payouts, more than doubling over approximately eight years. The FY2020 interim payout of ₹0.80 was an anomaly likely linked to COVID-19-related capital preservation. The stabilisation at ₹5.00 for two consecutive years suggests the company may be consolidating its payout policy at this level rather than pursuing further near-term increases.

Company Background

FDC Limited is a Mumbai-based pharmaceutical company engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs). The company operates across domestic branded generics, international generics, and consumer healthcare segments. Its product portfolio includes established brands in oral rehydration salts, ophthalmics, and anti-infectives.

What This Means for Investors

The flat dividend payout for FY2026 relative to FY2025 signals stability in the company's capital return framework, though it offers no incremental yield improvement for existing holders. Investors tracking FDC for income generation should note that the payout ratio and absolute dividend have held steady even as full-year FY2026 results are now published. The absence of a separate final dividend announcement following the results board meeting on May 27, 2026, suggests the February 2026 interim dividend constitutes the total distribution for the year. Investors should await the detailed profit and loss data from the Q4 FY2026 results filing to assess earnings coverage of the dividend and any changes in profitability trends.